Skip to main content
. 2019 Dec 23;11(1):14. doi: 10.3390/genes11010014

Figure 1.

Figure 1

Cell-free DNA biomarker discovery for PDAC management. Tissue- and disease-specific DNA methylation signatures are identified in the circulating pool of cfDNA molecules. Integration of sequence data for disease-specific mutation would enhance the overall diagnostic and prognostic sensitivity. Gene names: high methylation level is indicated in bold. Dashed line: pre-neoplastic stage.